A novel prognostic score (IPS-3), comprised of only three of the seven IPS-7 indicators (age ≥45, stage IV, haemoglobin <105 g/l), was recently proposed as a simplified model for advanced-stage classic Hodgkin lymphoma (cHL). We aimed to validate this model in advanced-stage cHL patients treated with doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) in British Columbia. The estimated five-year freedom from progression (FFP) for scores of 0, 1, 2 and 3 were very similar to the original report at 84%, 76%, 72% and 68% respectively. The IPS-3 score is highly reproducible in this independent dataset and its simplicity makes it appealing for everyday clinical practice.

中文翻译：

---

晚期经典霍奇金淋巴瘤患者的简化国际预后评分（IPS-3）的验证。

最近提出了一种新的预后评分（IPS-3），它​​仅包含七个IPS-7指标中的三个（年龄≥45，IV期，血红蛋白<105 g / l），作为晚期经典霍奇金的简化模型淋巴瘤（cHL）。我们旨在在不列颠哥伦比亚省接受阿霉素，博来霉素，长春碱，达卡巴嗪（ABVD）治疗的晚期cHL患者中验证该模型。评估的0、1、2和3分数五年发展自由度（FFP）与原始报告非常相似，分别为84％，76％，72％和68％。IPS-3分数在该独立数据集中具有很高的可重复性，其简单性使其吸引了日常临床实践。